MCID: CCN001
MIFTS: 49

Cocaine Dependence malady

Categories: Mental diseases

Aliases & Classifications for Cocaine Dependence

Summaries for Cocaine Dependence

Disease Ontology : 12 A drug dependence that is a psychological dependency on the regular use of cocaine.

MalaCards based summary : Cocaine Dependence is related to schizophrenia and personality disorder. An important gene associated with Cocaine Dependence is DRD2 (Dopamine Receptor D2), and among its related pathways/superpathways are Peptide ligand-binding receptors and Transmission across Chemical Synapses. The drugs Ethanol and Dopamine have been mentioned in the context of this disorder. Affiliated tissues include brain, heart and pituitary, and related phenotypes are behavior/neurological and endocrine/exocrine gland

Wikipedia : 71 Cocaine dependence is a psychological desire to use cocaine regularly. Cocaine overdose may result in... more...

Related Diseases for Cocaine Dependence

Diseases related to Cocaine Dependence via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 103)
id Related Disease Score Top Affiliating Genes
1 schizophrenia 29.7 DBH DRD2 DRD3 PRL SLC6A3 SLC6A4
2 personality disorder 29.6 DRD2 DRD3 OPRM1 PDYN POMC SLC6A3
3 cocaine intoxication 10.9
4 psychotic disorder 10.5
5 sphenoorbital meningioma 10.3 DRD2 DRD3
6 schizoid personality disorder 10.3 DRD3 SLC6A4
7 rhinoscleroma 10.3 DRD2 PRL
8 lung occult small cell carcinoma 10.2 DRD2 PRL
9 intracranial cavernous angioma 10.2 DRD2 SLC6A3 SLC6A4
10 african histoplasmosis 10.2 POMC PRL
11 splenic abscess 10.2 DRD2 SLC6A3 SLC6A4
12 congenital tricuspid stenosis 10.2 POMC PRL
13 usher syndrome 10.2 DRD2 DRD3 SLC6A3
14 strongyloidiasis 10.2 DRD2 SLC6A3 SLC6A4
15 intermittent squint 10.2 POMC PRL
16 cavernous hemangioma 10.2 DRD2 DRD3 SLC6A3
17 pfeiffer rockelein syndrome 10.2 DRD2 PRL
18 vertebral artery occlusion 10.2 POMC PRL
19 ornithosis 10.2 DRD2 PRL SLC6A4
20 extragonadal nonseminomatous germ cell tumor 10.2 POMC PRL
21 scoliosis 10.2 DBH DRD2 SLC6A3
22 wheat allergy 10.2 POMC PRL
23 pancreatic colloid cystadenoma 10.2 POMC PRL
24 olfactory nerve neoplasm 10.2 POMC PRL
25 alzheimer disease 17 10.2 DRD3 PRL SLC6A4
26 hypocalcemia, autosomal dominant 2 10.2 PDYN SLC6A3
27 autism 19 10.2 DBH DRD2 SLC6A3
28 interstitial emphysema 10.2 DBH DRD2 SLC6A4
29 hemochromatosis, type 2a 10.2 DRD2 DRD3 SLC6A3
30 aortic valve disease 2 10.2 DBH DRD2 SLC6A3
31 nonparalytic poliomyelitis 10.2 POMC PRL
32 teratoma with malignant transformation 10.2 DRD2 DRD3
33 pulmonary neuroendocrine tumor 10.1 DRD2 POMC PRL
34 dacryoadenitis 10.1 POMC PRL
35 c8 deficiency, type ii 10.1 DRD2 DRD3 OPRM1
36 infections, recurrent, with encephalopathy, hepatic dysfunction, and cardiovasuclar malformations 10.1 DRD2 POMC PRL
37 hereditary multiple exostoses 10.1 DRD2 POMC SLC6A4
38 anodontia 10.1 SLC6A3 SLC6A4
39 bile acid synthesis defect, congenital, 4 10.1 DRD2 POMC PRL
40 cold-induced sweating syndrome 2 10.1 DRD2 POMC PRL
41 adamantinous craniopharyngioma 10.1 DRD2 POMC PRL
42 extraosseous chondrosarcoma 10.1 PDYN POMC SLC6A4
43 acute contagious conjunctivitis 10.1 DRD2 OPRM1 PDYN
44 benign epilepsy with centrotemporal spikes 10.1 DRD2 POMC SLC6A4
45 pyromania 10.1 DRD2 DRD3 SLC6A3 SLC6A4
46 peripheral vertigo 10.1 OPRK1 OPRM1
47 cecal benign neoplasm 10.1 DRD2 DRD3 SLC6A3 SLC6A4
48 euthyroid sick syndrome 10.1 DRD2 SLC6A4
49 hemolytic anemia, cd59-mediated, with or without immune-mediated polyneuropathy 10.1 POMC PRL SLC6A4
50 brain glioblastoma multiforme 10.1 DRD2 DRD3 SLC6A3 SLC6A4

Graphical network of the top 20 diseases related to Cocaine Dependence:



Diseases related to Cocaine Dependence

Symptoms & Phenotypes for Cocaine Dependence

MGI Mouse Phenotypes related to Cocaine Dependence:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.22 CHRNA3 CHRNA5 CHRNB3 DBH DRD2 DRD3
2 endocrine/exocrine gland MP:0005379 9.92 DBH DRD2 OPRK1 OPRM1 POMC PRL
3 adipose tissue MP:0005375 9.91 DBH DRD2 DRD3 OPRM1 PDYN POMC
4 growth/size/body region MP:0005378 9.91 CHRNA3 DBH DRD2 DRD3 OPRM1 PDYN
5 homeostasis/metabolism MP:0005376 9.9 CHRNA3 DBH DRD2 DRD3 OPRK1 OPRM1
6 digestive/alimentary MP:0005381 9.85 CHRNA3 DRD2 DRD3 OPRK1 OPRM1 PDYN
7 integument MP:0010771 9.61 DBH DRD2 OPRK1 OPRM1 PDYN POMC
8 nervous system MP:0003631 9.4 SLC6A4 CHRNA3 CHRNA5 DBH DRD2 DRD3

Drugs & Therapeutics for Cocaine Dependence

Drugs for Cocaine Dependence (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 353)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ethanol Approved Phase 4,Phase 3,Phase 2,Phase 1 64-17-5 702
2
Dopamine Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 51-61-6, 62-31-7 681
3
Cocaine Approved, Illicit Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 50-36-2 5760 446220
4
Heroin Approved, Illicit Phase 4,Phase 3,Phase 2,Phase 1 561-27-3 5462328
5
Risperidone Approved, Investigational Phase 4,Phase 2,Phase 1 106266-06-2 5073
6
Amphetamine Approved, Illicit Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 300-62-9 5826 3007
7
Lidocaine Approved, Vet_approved Phase 4,Phase 2 137-58-6 3676
8
Ondansetron Approved Phase 4,Phase 2 99614-02-5 4595
9
Methamphetamine Approved, Illicit Phase 4,Phase 3,Phase 2 537-46-2 10836
10
Methadone Approved Phase 4,Phase 2,Phase 3,Phase 1 76-99-3 4095
11
Naltrexone Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 16590-41-3 5360515
12
Modafinil Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 68693-11-8 4236
13
Biperiden Approved Phase 4,Phase 3,Phase 2 514-65-8 2381
14
Armodafinil Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 112111-43-0
15
Lamotrigine Approved, Investigational Phase 4,Phase 3,Phase 2 84057-84-1 3878
16
Carbamazepine Approved, Investigational Phase 4,Phase 2 298-46-4 2554
17
Nicotine Approved Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1 54-11-5 942 89594
18
Naloxone Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1 465-65-6 5284596
19
Bupropion Approved Phase 4,Phase 3,Phase 2,Early Phase 1 34841-39-9, 34911-55-2 444
20
Disulfiram Approved Phase 4,Phase 2,Phase 1 97-77-8 3117
21
Oxytocin Approved, Vet_approved Phase 4,Phase 2,Phase 3 50-56-6 439302 53477758
22
Buprenorphine Approved, Illicit, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1 52485-79-7 40400 644073
23
Acetylcysteine Approved, Investigational Phase 4,Phase 2,Phase 1,Early Phase 1 616-91-1 12035
24
Azacitidine Approved, Investigational Phase 4 320-67-2 9444
25
Caffeine Approved, Nutraceutical Phase 4,Phase 2,Phase 3,Phase 1 58-08-2 2519
26
Choline Approved, Nutraceutical Phase 4,Phase 3 62-49-7 305
27 Analgesics Phase 4,Phase 2,Phase 3,Phase 1
28 Dopamine agonists Phase 4,Phase 2,Phase 3,Phase 1
29
Serotonin Phase 4,Phase 2,Phase 3,Phase 1 50-67-9 5202
30 Muscarinic Antagonists Phase 4,Phase 3,Phase 2,Phase 1
31 Cholinergic Agents Phase 4,Phase 3,Phase 2,Phase 1
32 Cholinergic Antagonists Phase 4,Phase 3,Phase 2,Phase 1
33 Serotonin Agents Phase 4,Phase 2,Phase 3,Phase 1
34 Adrenergic Agents Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
35 Narcotic Antagonists Phase 4,Phase 3,Phase 2,Phase 1
36 Serotonin Antagonists Phase 4,Phase 2,Phase 1
37 Narcotics Phase 4,Phase 3,Phase 2,Phase 1
38 Gastrointestinal Agents Phase 4,Phase 2,Phase 1
39 Sodium Channel Blockers Phase 4,Phase 3,Phase 2,Phase 1
40 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
41 Neurotransmitter Uptake Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
42 Cytochrome P-450 CYP3A Inducers Phase 4,Phase 3,Phase 2,Phase 1
43 Dermatologic Agents Phase 4,Phase 2
44 Analgesics, Opioid Phase 4,Phase 2,Phase 3,Phase 1
45 Tranquilizing Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
46 Anesthetics Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
47 Parasympatholytics Phase 4,Phase 3,Phase 2,Phase 1
48 Diuretics, Potassium Sparing Phase 4,Phase 3,Phase 2,Phase 1
49 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
50 Anesthetics, Local Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1

Interventional clinical trials:

(show top 50) (show all 406)
id Name Status NCT ID Phase
1 Efficacy of Caffeine, With and Without Biperiden, as a Maintenance Treatment for Cocaine Dependence Unknown status NCT00495183 Phase 4
2 Pharmacologic MRI in Cocaine Addiction Unknown status NCT01652378 Phase 4
3 Cognitive Correlates of Substance Abuse - 11 Unknown status NCT00000346 Phase 4
4 Citicoline for Bipolar 1 Disorder and Cocaine Dependence Completed NCT00619723 Phase 4
5 An Add-On Trial of Quetiapine in Patients With Bipolar Disorder and Cocaine Dependence Completed NCT00223210 Phase 4
6 Lamotrigine add-on Therapy for Bipolar Disorder and Cocaine Dependency Completed NCT00280293 Phase 4
7 Pathophysiological Subtyping of Abnormalities in Cocaine Dependence - 9 Completed NCT00015275 Phase 4
8 Neurobiological Adaptations and Pharmacological Interventions in Cocaine Addiction Completed NCT02626494 Phase 4
9 Quetiapine for Cocaine Use and Cravings Completed NCT00232336 Phase 4
10 Pharmacotherapy and Intensive Treatment - 2 Completed NCT00000218 Phase 4
11 Effects of Modafinil in Methamphetamine Dependence Completed NCT00751023 Phase 4
12 Seroquel Therapy for Substance Use Disorders Comorbid With Schizophrenia Completed NCT00208143 Phase 4
13 The Maternal Lifestyle Study (MLS) Completed NCT00059540 Phase 4
14 Brain Changes in Stimulant Dependent Subjects - 8 Completed NCT00000343 Phase 4
15 Bupropion for ADHD in Adolescents With Substance Use Disorder Completed NCT00936299 Phase 4
16 Buprenorphine Maintenance vs. Detoxification in Prescription Opioid Dependence Completed NCT00555425 Phase 4
17 Counseling for Primary Care Office-based Buprenorphine Completed NCT00595764 Phase 4
18 A Study of VIVITROL in the Prevention of Re-arrest and Re-incarceration Completed NCT01453374 Phase 4
19 Effect of N-acetylcysteine on Alcohol and Cocaine Use Disorders: A Double-Blind Randomized Controlled Trial. Recruiting NCT03018236 Phase 4
20 Oxytocin and Cognitive Behavioral Therapy in Drug Dependence Terminated NCT00975416 Phase 4
21 A PET Exploration of the Mechanism of Action of Dopamine Beta-hydroxylase Inhibition in Cocaine Addicts Withdrawn NCT02134002 Phase 4
22 Effectiveness of Topiramate in Treating Cocaine Dependent Individuals - 1 Unknown status NCT00249691 Phase 3
23 Novel Pharmacotherapy for Dual Dependence Unknown status NCT00448825 Phase 3
24 Comparing Acute and Continuous Drug Abuse Treatment: A Randomized Clinical Trial Unknown status NCT01003496 Phase 3
25 Imaging the Neurobiology of Behavioral and Medication Treatment for Cocaine Dependence Completed NCT01468012 Phase 2, Phase 3
26 Selegiline Transdermal System for the Treatment of Cocaine Dependence - 1 Completed NCT00032929 Phase 3
27 Study of Adderall-XR for the Treatment of Adult Attention Deficit Hyperactivity Disorder and Cocaine Dependence Completed NCT00553319 Phase 2, Phase 3
28 Brain Imaging Study of the Effects of Modafinil in Cocaine Addiction Completed NCT00701532 Phase 3
29 Naltrexone in Two Models of Psychosocial Treatments for Cocaine and Alcohol Dependence Completed NCT00167232 Phase 3
30 Dose Response Trial of Pergolide for Cocaine Dependence - 1 Completed NCT00000248 Phase 3
31 Naltrexone in Two Models of Psychosocial Treatments for Cocaine and Alcohol Dependence - 1 Completed NCT00218660 Phase 3
32 Vigabatrin for the Treatment of Cocaine Dependency Completed NCT01281202 Phase 2, Phase 3
33 Adaptive Treatment for Alcohol and Cocaine Dependence Completed NCT01032135 Phase 2, Phase 3
34 Cocaine Use Reduction With Buprenorphine Completed NCT01402492 Phase 2, Phase 3
35 Cocaine/Crack and Reduction of Compulsion With Biperiden Completed NCT01251393 Phase 3
36 Progesterone Treatment for Cocaine-dependent Women: A Pilot Study Completed NCT00632099 Phase 2, Phase 3
37 Clinical Neurobiology of Serotonin and Addiction Completed NCT00732901 Phase 2, Phase 3
38 Efficacy of Caffeine, With and Without Biperiden, in the Detoxification of Cocaine Dependent Patients Completed NCT00495092 Phase 2, Phase 3
39 Effect of Nefazodone on Relapse in Females With Cocaine Abuse - 10 Completed NCT00000293 Phase 3
40 Smoking-Cessation and Stimulant Treatment (S-CAST) Completed NCT01077024 Phase 3
41 Treatment of Adult Attention Deficit Hyperactivity Disorder (ADHD) in Methadone Patients - 1 Completed NCT00061087 Phase 2, Phase 3
42 Trial of Citicoline Therapy in Patients With Mania or Hypomania and Cocaine Abuse/Dependence Completed NCT00223236 Phase 3
43 Reengineering Methadone Treatment Study of Patient-centered Methadone Treatment Completed NCT01442493 Phase 3
44 An Eval of Neurocognitive Function, Oxidative Damage, and Their Association With Outcomes in METH and Cocaine Abusers. Completed NCT00628927 Phase 3
45 The German Project of Heroin Assisted Treatment of Opiate Dependent Patients Completed NCT00268814 Phase 3
46 "Effectiveness of a Brief Intervention for Substances Consumption Linked to the Alcohol, Smoking and Substance Involvement Screening Test (ASSIST): A Randomized Control Trial in Chilean Primary Care." Completed NCT01573416 Phase 3
47 Combination Therapy in Dual Diagnosis Bipolar Rapid Cycling Completed NCT00221975 Phase 3
48 Lithium and Divalproex for the Treatment of Comorbid Rapid Cycling Bipolar Disorder and Substance Abuse Disorder Completed NCT00194129 Phase 3
49 Methadone Maintenance for Prisoners Completed NCT00378079 Phase 3
50 Buprenorphine for Prisoners Completed NCT00574067 Phase 3

Search NIH Clinical Center for Cocaine Dependence

Genetic Tests for Cocaine Dependence

Anatomical Context for Cocaine Dependence

MalaCards organs/tissues related to Cocaine Dependence:

39
Brain, Heart, Pituitary, Testes, Cortex, Temporal Lobe, Thalamus

Publications for Cocaine Dependence

Articles related to Cocaine Dependence:

(show top 50) (show all 602)
id Title Authors Year
1
Reply to: kynurenic acid and alcohol and cocaine dependence: novel effects and multiple mechanisms? ( 27896378 )
2017
2
Netrin G1: its downregulation in the nucleus accumbens of cocaine-conditioned mice and genetic association in human cocaine dependence. ( 28074533 )
2017
3
Kynurenic acid and alcohol and cocaine dependence: novel effects and multiple mechanisms? ( 27885412 )
2017
4
Psychotic symptoms associated with the use of dopaminergic drugs, in patients with cocaine dependence or abuse. ( 27009114 )
2016
5
Topiramate for Cocaine Dependence: A Systematic Review and Meta-Analysis of Randomized Control Trials. ( 26826006 )
2016
6
A Highly Polymorphic Copy Number Variant in the NSF Gene is Associated with Cocaine Dependence. ( 27498889 )
2016
7
Characterization of white matter integrity deficits in cocaine-dependent individuals with substance-induced psychosis compared with non-psychotic cocaine users. ( 26833821 )
2016
8
Cocaine-induced Psychosis and Brain-derived Neurothrophic Factor in Patients with Cocaine Dependence: Report of Two Cases. ( 26792050 )
2016
9
A randomized factorial trial of disulfiram and contingency management to enhance cognitive behavioral therapy for cocaine dependence. ( 26817621 )
2016
10
Attenuated neural response to emotional cues in cocaine-dependence: a preliminary analysis of gender differences. ( 27441590 )
2016
11
Cocaine dependence and thalamic functional connectivity: a multivariate pattern analysis. ( 27556009 )
2016
12
Assessing the effects of cocaine dependence and pathological gambling using group-wise sparse representation of natural stimulus FMRI data. ( 27704410 )
2016
13
Mixed-amphetamine salts increase abstinence from marijuana in patients with co-occurring attention-deficit/hyperactivity disorder and cocaine dependence. ( 28051838 )
2016
14
Just showing up is not enough: Homework adherence and outcome in cognitive-behavioral therapy for cocaine dependence. ( 27454780 )
2016
15
Subcortical grey matter alterations in cocaine dependent individuals with substance-induced psychosis compared to non-psychotic cocaine users. ( 27499362 )
2016
16
Antipsychotic medications for cocaine dependence. ( 26992929 )
2016
17
Buprenorphinea88+a88Naloxone plus Naltrexone for the Treatment of Cocaine Dependence: The Cocaine Use Reduction with Buprenorphine (CURB) Study. ( 26948856 )
2016
18
Modafinil and sleep architecture in an inpatient-outpatient treatment study of cocaine dependence. ( 26777774 )
2016
19
Dissociable Effects of Cocaine-Dependence on Reward Processes: The Role of Acute Cocaine and Craving. ( 27545986 )
2016
20
Psychostimulant drugs for cocaine dependence. ( 27670244 )
2016
21
Successful classification of cocaine dependence using brain imaging: a generalizable machine learning approach. ( 27766943 )
2016
22
Efficacy of topiramate in the treatment of crack cocaine dependence: a double-blind, randomized, placebo-controlled trial. ( 27046312 )
2016
23
Effective drug therapy for cocaine dependence: a milestone. ( 27015910 )
2016
24
Polysomnographic measures of sleep in cocaine dependence and alcohol dependence: Implications for age-related loss of slow wave, stage 3 sleep. ( 26749502 )
2016
25
Clinical differences between cocaine-dependent patients with and without antisocial personality disorder. ( 27839828 )
2016
26
Neurofunctional Reward Processing Changes in Cocaine Dependence During Recovery. ( 26792441 )
2016
27
Effect of Continuing Care for Cocaine Dependence on HIV Sex-Risk Behaviors. ( 27224980 )
2016
28
Placebo-controlled evaluation of a bioengineered, cocaine-metabolizing fusion protein, TV-1380 (AlbuBChE), in the treatment of cocaine dependence. ( 27394932 )
2016
29
A delta-opioid receptor genetic variant is associated with abstinence prior to and during cocaine dependence treatment. ( 27449273 )
2016
30
Psychiatric comorbidity in a sample of cocaine-dependent outpatients seen in the Community of Madrid drug addiction care network. ( 26990385 )
2016
31
Crack-cocaine dependence and aging: effects on working memory. ( 27111700 )
2016
32
Utility of Machine-Learning Approaches to Identify Behavioral Markers for Substance Use Disorders: Impulsivity Dimensions as Predictors of Current Cocaine Dependence. ( 27014100 )
2016
33
Independent effects of HIV infection and cocaine dependence on neurocognitive impairment in a community sample living in the southern United States. ( 25697913 )
2015
34
Effect of Patient Choice in an Adaptive Sequential Randomization Trial of Treatment for Alcohol and Cocaine Dependence. ( 26214544 )
2015
35
Effects of adverse childhood experiences on the association between intranasal oxytocin and social stress reactivity among individuals with cocaine dependence. ( 26231584 )
2015
36
Self-reported impulsivity is negatively correlated with amygdalar volumes in cocaine dependence. ( 26187551 )
2015
37
A double blind, placebo controlled trial of modafinil for the treatment of cocaine dependence without co-morbid alcohol dependence. ( 26320827 )
2015
38
Catehol-o-methyltransferase gene Val158met polymorphism as a potential predictor of response to computer-assisted delivery of cognitive-behavioral therapy among cocaine-dependent individuals: Preliminary findings from a randomized controlled trial. ( 25930952 )
2015
39
Dopamine agonists for the treatment of cocaine dependence. ( 26014366 )
2015
40
In the face of threat: neural and endocrine correlates of impaired facial emotion recognition in cocaine dependence. ( 26080087 )
2015
41
Increased corticolimbic connectivity in cocaine dependence versus pathological gambling is associated with drug severity and emotion-related impulsivity. ( 25818325 )
2015
42
Brain substrates of social decision-making in dual diagnosis: cocaine dependence and personality disorders. ( 26442666 )
2015
43
A Randomized Placebo-Controlled Trial of Targeted Prefrontal Cortex Modulation with Bilateral tDCS in Patients with Crack-Cocaine Dependence. ( 26065432 )
2015
44
Changes in brain-derived neurotrophic factor (BDNF) during abstinence could be associated with relapse in cocaine-dependent patients. ( 25592977 )
2015
45
Deep Brain Stimulation for Refractory Cocaine Dependence. ( 26235303 )
2015
46
Self-reported cue-induced physical symptoms of craving as an indicator of cocaine dependence. ( 26541796 )
2015
47
A preliminary study of dopamine D2/3 receptor availability and social status in healthy and cocaine dependent humans imaged with [(11)C](+)PHNO. ( 26164205 )
2015
48
Transcriptomic and genetic studies identify NFAT5 as a candidate gene for cocaine dependence. ( 26506053 )
2015
49
Impaired Bayesian learning for cognitive control in cocaine dependence. ( 25869543 )
2015
50
Anticonvulsants for cocaine dependence. ( 25882271 )
2015

Variations for Cocaine Dependence

Expression for Cocaine Dependence

Search GEO for disease gene expression data for Cocaine Dependence.

Pathways for Cocaine Dependence

Pathways related to Cocaine Dependence according to GeneCards Suite gene sharing:

id Super pathways Score Top Affiliating Genes
1
Show member pathways
12.59 CHRNA3 CHRNA5 CHRNB3 DRD2 DRD3 OPRK1
2
Show member pathways
12.57 CHRNA3 CHRNA5 CHRNB3 SLC6A3 SLC6A4
3
Show member pathways
12.4 CHRNA3 DRD2 DRD3 SLC6A3
4
Show member pathways
11.61 DRD2 PDYN SLC6A3
5
Show member pathways
11.36 CHRNA3 CHRNA5 CHRNB3
6
Show member pathways
11.27 CHRNA3 CHRNA5 DRD2 DRD3
7
Show member pathways
10.97 DBH SLC6A3 SLC6A4
8
Show member pathways
10.89 SLC6A3 SLC6A4
9 10.8 DRD2 DRD3

GO Terms for Cocaine Dependence

Cellular components related to Cocaine Dependence according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 integral component of plasma membrane GO:0005887 9.91 DRD2 DRD3 OPRK1 OPRM1 SLC6A3 SLC6A4
2 synapse GO:0045202 9.78 CHRNA3 CHRNA5 CHRNB3 OPRK1
3 neuronal cell body GO:0043025 9.71 CHRNA3 OPRK1 PDYN SLC6A3
4 dendrite GO:0030425 9.55 CHRNA3 DRD2 OPRK1 OPRM1 PDYN
5 perikaryon GO:0043204 9.54 DRD2 OPRK1 OPRM1
6 axon terminus GO:0043679 9.43 DRD2 OPRK1 PDYN
7 neuron projection GO:0043005 9.35 CHRNB3 OPRK1 OPRM1 SLC6A3 SLC6A4
8 acetylcholine-gated channel complex GO:0005892 8.8 CHRNA3 CHRNA5 CHRNB3
9 integral component of membrane GO:0016021 10.16 CHRNA3 CHRNA5 CHRNB3 DBH DRD2 DRD3
10 plasma membrane GO:0005886 10.02 CHRNA3 CHRNA5 CHRNB3 DRD2 DRD3 OPRK1

Biological processes related to Cocaine Dependence according to GeneCards Suite gene sharing:

(show top 50) (show all 52)
id Name GO ID Score Top Affiliating Genes
1 response to drug GO:0042493 9.97 DRD2 DRD3 PRL SLC6A3 SLC6A4
2 chemical synaptic transmission GO:0007268 9.88 CHRNA5 DBH OPRK1 OPRM1 PDYN
3 neuropeptide signaling pathway GO:0007218 9.81 OPRK1 OPRM1 PDYN POMC
4 visual learning GO:0008542 9.78 DBH DRD2 DRD3
5 negative regulation of adenylate cyclase activity GO:0007194 9.72 DRD2 DRD3 OPRM1
6 negative regulation of blood pressure GO:0045776 9.71 DRD2 DRD3
7 associative learning GO:0008306 9.71 DBH DRD2
8 regulation of sensory perception of pain GO:0051930 9.71 OPRK1 OPRM1
9 eating behavior GO:0042755 9.71 OPRK1 OPRM1
10 response to amphetamine GO:0001975 9.71 DBH DRD2 DRD3
11 excitatory postsynaptic potential GO:0060079 9.71 CHRNA3 CHRNA5 CHRNB3 OPRM1
12 neuromuscular synaptic transmission GO:0007274 9.7 CHRNA5 CHRNB3
13 regulation of multicellular organism growth GO:0040014 9.7 DRD3 PRL
14 arachidonic acid secretion GO:0050482 9.7 DRD2 DRD3
15 regulation of dopamine secretion GO:0014059 9.7 DRD2 DRD3
16 synaptic transmission, cholinergic GO:0007271 9.7 CHRNA3 CHRNA5 CHRNB3
17 dopamine receptor signaling pathway GO:0007212 9.69 DRD2 DRD3
18 response to iron ion GO:0010039 9.69 DRD2 SLC6A3
19 synaptic transmission, dopaminergic GO:0001963 9.69 DRD2 DRD3
20 estrous cycle GO:0044849 9.68 OPRK1 OPRM1
21 neurotransmitter biosynthetic process GO:0042136 9.68 SLC6A3 SLC6A4
22 maternal behavior GO:0042711 9.68 DBH OPRK1
23 dopamine metabolic process GO:0042417 9.68 DRD2 DRD3
24 ammonium transmembrane transport GO:0072488 9.67 SLC6A3 SLC6A4
25 positive regulation of renal sodium excretion GO:0035815 9.67 DRD2 DRD3
26 negative regulation of protein secretion GO:0050709 9.67 DRD2 DRD3
27 behavioral response to cocaine GO:0048148 9.67 DRD2 DRD3 OPRK1
28 G-protein coupled receptor internalization GO:0002031 9.66 DRD2 DRD3
29 adenylate cyclase-inhibiting dopamine receptor signaling pathway GO:0007195 9.66 DRD2 DRD3
30 adenylate cyclase-activating dopamine receptor signaling pathway GO:0007191 9.65 DRD3 OPRM1
31 adenohypophysis development GO:0021984 9.65 DRD2 SLC6A3
32 monoamine transport GO:0015844 9.65 SLC6A3 SLC6A4
33 dopamine catabolic process GO:0042420 9.64 DBH SLC6A3
34 opioid receptor signaling pathway GO:0038003 9.64 OPRK1 OPRM1
35 regulation of cAMP metabolic process GO:0030814 9.63 DRD2 DRD3
36 behavioral response to nicotine GO:0035095 9.63 CHRNA3 CHRNA5
37 behavioral response to ethanol GO:0048149 9.63 DBH DRD2 OPRM1
38 response to ethanol GO:0045471 9.63 DRD2 DRD3 OPRK1 OPRM1 PRL SLC6A3
39 dopamine uptake involved in synaptic transmission GO:0051583 9.62 SLC6A3 SLC6A4
40 regulation of dopamine uptake involved in synaptic transmission GO:0051584 9.62 DRD2 DRD3
41 response to nicotine GO:0035094 9.62 CHRNA5 CHRNB3 DRD2 SLC6A3
42 sensory perception GO:0007600 9.61 OPRK1 OPRM1 PDYN
43 negative regulation of dopamine receptor signaling pathway GO:0060160 9.6 DRD2 DRD3
44 acid secretion GO:0046717 9.59 DRD2 DRD3
45 response to histamine GO:0034776 9.58 DRD2 DRD3
46 adenylate cyclase-inhibiting opioid receptor signaling pathway GO:0031635 9.57 OPRK1 OPRM1
47 regulation of locomotion involved in locomotory behavior GO:0090325 9.56 DRD2 DRD3
48 response to morphine GO:0043278 9.56 DRD2 DRD3 OPRK1 OPRM1
49 prepulse inhibition GO:0060134 9.54 DRD2 DRD3 SLC6A3
50 response to cocaine GO:0042220 9.35 DRD2 DRD3 OPRK1 OPRM1 SLC6A3

Molecular functions related to Cocaine Dependence according to GeneCards Suite gene sharing:

(show all 14)
id Name GO ID Score Top Affiliating Genes
1 extracellular ligand-gated ion channel activity GO:0005230 9.58 CHRNA3 CHRNA5 CHRNB3
2 neuropeptide binding GO:0042923 9.54 OPRK1 OPRM1
3 neurotransmitter:sodium symporter activity GO:0005328 9.52 SLC6A3 SLC6A4
4 acetylcholine receptor activity GO:0015464 9.51 CHRNA3 CHRNA5
5 ligand-gated ion channel activity GO:0015276 9.5 CHRNA3 CHRNA5 CHRNB3
6 opioid receptor activity GO:0004985 9.49 OPRK1 OPRM1
7 dopamine neurotransmitter receptor activity, coupled via Gi/Go GO:0001591 9.48 DRD2 DRD3
8 monoamine transmembrane transporter activity GO:0008504 9.46 SLC6A3 SLC6A4
9 dopamine neurotransmitter receptor activity GO:0004952 9.43 DRD2 DRD3
10 acetylcholine binding GO:0042166 9.43 CHRNA3 CHRNA5 CHRNB3
11 dopamine:sodium symporter activity GO:0005330 9.37 SLC6A3 SLC6A4
12 acetylcholine-gated cation-selective channel activity GO:0022848 9.33 CHRNA3 CHRNA5 CHRNB3
13 drug binding GO:0008144 9.26 CHRNB3 DRD2 DRD3 SLC6A3
14 dopamine binding GO:0035240 8.8 DRD2 DRD3 SLC6A3

Sources for Cocaine Dependence

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....